Additionally, Saha acquired 87,496 ordinary shares through the exercise of share options at a price of $5.84 per share, totaling approximately $510,976. After these transactions, Saha holds 575,661 shares directly and 38,000 shares indirectly through a trust. With a current market capitalization of $2.3 billion, InvestingPro analysis indicates the stock is currently overvalued compared to its Fair Value. Subscribers can access 12 additional ProTips and a comprehensive Pro Research Report for deeper insights into CNTA's valuation and growth prospects. With a current market capitalization of $2.3 billion, InvestingPro analysis indicates the stock is currently overvalued compared to its Fair Value. Subscribers can access 12 additional ProTips and a comprehensive Pro Research Report for deeper insights into CNTA's valuation and growth prospects.
Additionally, Saha acquired 87,496 ordinary shares through the exercise of share options at a price of $5.84 per share, totaling approximately $510,976. After these transactions, Saha holds 575,661 shares directly and 38,000 shares indirectly through a trust.
In other recent news, Centessa Pharmaceuticals has seen several positive developments. Leerink Partners raised the stock's price target to $24, maintaining an Outperform rating, following a promising update to Centessa's Phase 1 ORX750 program. The firm also increased its projections for Centessa's total company sales in 2032 by 4%, from $1.2 billion to $1.3 billion, and earnings per share (EPS) by 18%, from $4.42 to $5.21.
Guggenheim maintained a Buy rating on Centessa shares, lifting the price target to $28, highlighting recent strategic developments, particularly updates for ORX750. BMO Capital Markets also maintained its Outperform rating and a $35.00 price target for Centessa, based on new data for ORX142, which supports the company's leading position in the orexin agonist market.
Oppenheimer retained an Outperform rating and a steady price target of $24.00 for Centessa, buoyed by promising preclinical data for ORX142. Morgan Stanley (NYSE:MS) upgraded Centessa to Overweight, raising the price target to $26, following the promising interim Phase 1 results of Centessa's ORX750 study.
These recent developments highlight Centessa's ongoing efforts in the pharmaceutical industry, with a particular focus on its product pipeline. Investors are advised to watch for further developments, including additional Phase 1 data on ORX750 and updates on other pipeline candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.